In the News

Contact: Peter Buonanno – [email protected], 704-989-5501 WASHINGTON, D.C. (July 28, 2021) — Today, the Global Alzheimer’s Platform Foundation® (GAP) announced that Gates Ventures and the Alzheimer’s Disease Data Initiative (ADDI) will join the list of biopharma, technology, and nonprofit partners who are contributing to GAP’s breakthrough Alzheimer’s study, Bio-Hermes. Bio-Hermes is the first-ever platform study […]

GAP-Net site Washington Univeristy in St. Louis’ Dr. Joy Snider about the pros and cons about the approval of Aduhelm (Aducanumab). The recent FDA approval of a new Alzheimer’s drug has some researchers concerned — aside from its $56,000-a-year price tag. It’s the first Alzheimer’s drug to be approved since 2003. It’s called aducanumab and is marketed […]

Dr. Tamiko Magee-Rodgers joins the BNC to discuss the new Alzheimer`s drug, Aduhelm, and the role of minorities in clinical trials. Originally shown on BNC on July 9, 2021.

GAP Net site, Great Lakes Clinical Trials, spoke The Chicago Defender about GAP’s Bio-Hermes study and the importance of minority communities getting involved in Alzheimer’s clinical trials. Chicago’s Great Lakes Clinical Trials is now enrolling volunteers with and without memory concerns in the Global Alzheimer’s Platform Foundation’s Bio-Hermes Study. The study seeks to evaluate how […]

GAP-Net site Kerwin Medical Center in Dallas and GAP President John Dwyer were featured in D Magazine talking about how the Bio-Hermes study is making it easier for diverse populations to participate in its new Alzheimer’s trial. Dallas-based Kerwin Medical Center is emphasizing diversity as it enrolls patients in the Global Alzheimer’s Platform Foundation’s (GAP) […]

GAP-Net site Butler Hospital Memory and Aging Program administered the first infusion of Aduhelm to a patient who wasn’t involved in the clinical trial. A U.S. hospital on Wednesday gave the first infusion of an expensive, controversial new Alzheimer’s drug from Biogen Inc before Medicare had even said what it will pay for – and with […]

GAP President John Dwyer spoke to THE CALL about the health disparities in Alzheimer’s research and treatment between Black and African Americans compared to whites. If you have a family member or loved one going through Dementia you probably wish that you could turn back the clock about 15 years or to a time when […]

John Dwyer, GAP President, spoke about the impact Abucanumab will have on Alzheimer’s research and clinical trials going forward. The arrival of the first new Alzheimer’s drug in two decades should have been a moment of celebration. But so far, the healthcare industry is feeling concerned. The US Food and Drug Administration approved the new medication, […]

GAP President John Dwyer spoke to Scrip Informa Pharma Intelligence about Biogen’s aducanumab, and how clinical trials are more important than ever since it’s FDA approval. The requirement for Biogen, Inc. and Eisai Co., Ltd. to conduct a Phase IV clinical trialas a condition of Aduhelm’s accelerated approval raises the question of whether Alzheimer’s disease […]

The talk radio station in Dallas, Texas, WBAP, recently interviewed GAP President John Dwyer. After the FDA approval of Biogen’s Aducanumab, they included GAP’s statement commending the FDA. WASHINGTON (AP)- Government health officials on approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment […]

Patients and Doctors Deserve the Ability to Consider Whether Aducanumab Will Deliver the Best Medical Outcome and Quality of Life Washington, DC (June 7, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation (GAP), a patient-centric organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on […]

GAP Chairman, George Vradenburg, talks about a bold approach that the National Institute of Health (NIH) can take by partnering with America’s best biotech and pharmaceutical research centers. The U.S. needs a bold initiative to achieve transformative progress in the fight against Alzheimer’s disease, cancer, cardiovascular disease, diabetes, and countless other diseases that cut lives […]

A student at GAP-Net site Northwestern University created Alzheimer’s Brain Box, a customized box to help engage the brain and enhance mood for those living with the disease. Weinberg second-year student Victoria Da Conceicao learned at a young age what it means to fight back against adversity. As a child, she always lived near her […]

GAP-Net site Princeton Medical Institute’s Dr. Jeffrey Apter was featured on NJ 101.5 and spoke about an Alzheimer’s drug that is taking a fresh approach on treating the disease. We’ve heard it called the long goodbye. I can only imagine how painful it is to have your parents go through the slow decline of dementia, […]

Research from GAP-Net site University of California, San Francisco finds retinal scans tie blood vessel deterioration to APOE4, the most prevalent genetic risk for Alzheimer’s disease. While it has been said that the eyes are a window to the soul, a new study shows they could be a means for understanding diseases of the brain. […]

The Bio-Hermes study will not close until 20% of its volunteers are Hispanic/Latinx, and/or African American/Black. This article is also available in Spanish. A clinical trial could lead to the creation of biomarker-based rapid Alzheimer’s tests. The research called Biohermes will include older Hispanics in the study, announced the Global Alzheimer’s Platform Foundation (GAP). The study will be carried out in […]

GAP-Net site, Inland Northwest Research, and GAP President, John Dwyer, talk about the Parkinson’s disease study, PADOVA, and what it hopes to achieve. A Parkinson’s disease clinical trial is launching at 120 global sites – including Spokane – to do a broader test of an investigational drug that in an earlier phase indicated it slowed […]

GAP-Net site, Clarity Clinical Research, was featured on CNYCentral about their participation in the Bio-Hermes study. Clarity Clinical Research, a Syracuse research group, is looking for volunteers in an Alzheimer’s risk study. The study includes three visits with no-cost amyloid PET scans that are designed to predict or possibly diagnose Alzheimer’s disease. Brain amyloid plaques […]

GAP President John Dwyer was on RochesterFirst.com to talk about the ground breaking Bio-Hermes study and what it means for the future of Alzheimer’s detection. Click here to watch the full interview.  In the next few years – we could expect Alzheimer’s detection to be as easy and accessible as ordering up a blood test, […]

GAP President John Dwyer spoke to Alzforum about the Bio-Hermes study. With disease-modifying treatments for Alzheimer’s disease potentially on the cusp of approval, there will be pressing demand for quick, simple ways to screen patients and determine if they have amyloid plaque in their brains. The current gold-standard diagnostics used in research—amyloid PET scans and […]

GAP-Net Site Clarity Clinical Research talks about their participation in GAP’s Bio-Hermes Study. Syracuse, N.Y. — A Syracuse research clinic is seeking volunteers for a brain scan that may help predict or diagnose Alzheimer’s disease before symptoms appear. Clarity Clinical Research is one of 10 clinics nationwide offering no cost Amyloid PET scans as part […]

GAP President John Dwyer was quoted in a New York Times article along side three Alzheimer’s volunteer participants in the donanemab clinical trial by Lilly, a GAP partner. Despite the urgent need for treatments to slow or stop Alzheimer’s disease, finding patients for clinical trials has been difficult and frustrating. Patients are often older. Their […]

Lilly, AbbVie, Merck, the Alzheimer’s Drug Discovery Foundation, and leading technology companies join the first platform study assessing various biomarker tests’ ability to predict the presence of Alzheimer’s Contact: Pamela Larkin – [email protected], 408-466-5952 Washington, DC (April 20, 2021) – Today, the Global Alzheimer’s Platform Foundation® (GAP) announced eleven biopharma, technology, and nonprofit partners who […]

GAP-Net site Inland Northwest Research LLC screened the first patient in the Roche PADOVA study for an investigational Parkinson’s disease drug. Spokane, Washington (April 12, 2021) – Inland Northwest Research, LLC screened the first patient worldwide for the Parkinson’s Disease PADOVA study. The Global Alzheimer’s Platform Foundation® (GAP) is helping study sponsor Roche (SIX: ROG) […]